Study details
Enrolling now
Promoting HIV Risk Reduction Among People Who Inject Drugs
Yale University
NCT IDNCT04738825ClinicalTrials.gov data as of Apr 2026
Target enrollment
526
Study length
about 4.7 years
Ages
18+
Locations
6 sites in CT, MA
What this study is about
This trial is testing a new approach called CoMPASS to help people who inject drugs reduce their risk of getting HIV. CoMPASS uses contingency management, which provides rewards for good behavior, along with support services and PrEP adherence. The goal is to see if this method helps prevent HIV infection.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Participate in Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Psychiatry / Mental Health, Infectious